ADMA Biologics, Inc. (NASDAQ:ADMA) Director Lawrence P. Guiheen Sells 9,000 Shares

ADMA Biologics, Inc. (NASDAQ:ADMA) Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

ADMA Biologics Price Performance

ADMA Biologics stock traded down $0.38 during midday trading on Wednesday, reaching $16.91. 5,468,410 shares of the stock were exchanged, compared to its average volume of 3,115,505. The company’s fifty day moving average is $14.69 and its 200-day moving average is $10.27. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. ADMA Biologics, Inc. has a 52 week low of $3.06 and a 52 week high of $19.34. The firm has a market cap of $3.94 billion, a PE ratio of -865.50 and a beta of 0.61.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The company had revenue of $107.20 million for the quarter, compared to the consensus estimate of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. During the same quarter last year, the business posted ($0.02) earnings per share. The firm’s revenue was up 78.4% compared to the same quarter last year. On average, sell-side analysts forecast that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

Institutional Trading of ADMA Biologics

Large investors have recently modified their holdings of the business. Mesirow Institutional Investment Management Inc. bought a new position in shares of ADMA Biologics in the first quarter worth approximately $17,221,000. Bank of Montreal Can purchased a new position in ADMA Biologics in the 2nd quarter worth approximately $17,886,000. D. E. Shaw & Co. Inc. increased its holdings in shares of ADMA Biologics by 26.8% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock worth $76,298,000 after buying an additional 1,442,799 shares during the last quarter. Castleark Management LLC purchased a new stake in shares of ADMA Biologics during the 1st quarter valued at $5,400,000. Finally, Hillsdale Investment Management Inc. lifted its holdings in shares of ADMA Biologics by 41,893.3% during the 1st quarter. Hillsdale Investment Management Inc. now owns 629,900 shares of the biotechnology company’s stock worth $4,157,000 after acquiring an additional 628,400 shares during the last quarter. Institutional investors own 75.68% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on ADMA. Cantor Fitzgerald upped their price target on shares of ADMA Biologics from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. HC Wainwright raised their price target on ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Mizuho lifted their price target on ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $15.50.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.